BMJ3d
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ3d
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Correspondence to Dr Sara Monti, Rheumatology, IRCCS Fondazione Policlinico S Matteo, Pavia 27100, Italy; sara.saramonti{at}gmail.com Different viral agents are associated with an increased risk of ...
BMJ3d
Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
BMJ3d
FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice
Objectives This study aims to investigate the role and mechanism of FGFR3 in macrophages and their biological effects on the pathology of arthritis. Methods Mice with conditional knockout of FGFR3 in ...
BMJ4d
Genetics of rheumatoid arthritis: 2018 status
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
BMJ5d
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive ...
BMJ6d
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...
BMJ7d
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...
BMJ11d
THU0178 Long term safety profile of methotrexate in patients with ra in routine care
Background Methotrexate is the anchor drug used most widely as monotherapy or combination therapy with other DMARDS & biologics in treatment of RA. It is widely perceived by clinicians to have ...
BMJ19d
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
Correspondence to Dr Annette H M van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, P.O. Box 9600, Leiden 2300 RC, The Netherlands; AvdHelm{at}lumc.nl Background ...
BMJ20d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ21d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...